AKTS

Aktis Oncology, Inc.

A clinical-stage biotech developing targeted alpha radiopharmaceuticals for solid tumors, Aktis Oncology builds its medicines from tiny engineered proteins called miniproteins that slip deep into tumors and clear quickly from the body. Its lead candidate targets Nectin-4, found on bladder and other cancers, while a second program targets B7-H3 for prostate and lung cancers. The company has a discovery collaboration with Eli Lilly and is building its own manufacturing facility.

CUSIP: 01021M104HealthcareUS2 holders

Ownership Activity Financials Filings

AKTS

AKTS

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Results of Operations and Financial Condition

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year